CareDx

CareDx is a US specialist in molecular diagnostic tests and digital software solutions for monitoring patients before and after organ transplants. The business model is based on non-invasive blood tests for early detection of organ rejection and integrated software for transplant centers, creating predictable and recurring revenue. After a period of regulatory challenges, CareDx has realigned to promote growth and stability. » Mais em finanzen.net

Caredx shares rose to a 52-week high of $53.71 and are currently trading at $53.54 (market capitalization $2.74 billion). Year-to-date performance is 275.74%, the Piotroski score is 9 and the PEG ratio is 0.22. In Q2 2026 Caredx beat estimates with adjusted EPS of $0.37 and revenue of $132 million and raised its full-year guidance. Canaccord Genuity initiated coverage with a buy rating and $65 price target; H.C. Wainwright maintained neutral with a $46 price target; an InvestingPro analysis currently sees the stock trading above its fair value. » Mais em de.investing.com

Caredx shares climbed to a 52-week high of $49.77 (current price $49.69) and show a year-to-date gain of 283.22%. InvestingPro considers the stock overvalued despite a market capitalization of $2.57 billion, but assigns a Piotroski score of 9 and a PEG of 0.2. In Q2 Caredx beat expectations with adjusted EPS of $0.37 (expectation $0.23) and revenue of about $132 million, driven by testing revenue of $99.9 million (+61% y/y). The company raised its full-year guidance; H.C. Wainwright maintains a “Neutral” rating with a $46 price target. » Mais em de.investing.com

Baron Discovery Fund said CareDx contributed positively to Q2 2026 performance after the fund increased its stake when shares traded near $11–$12 amid CMS MolDX draft LCD concerns. CareDx reported strong Q1 results with revenue up 39% y/y and testing volumes up 17% y/y, and completed deals to divest its lab products business and acquire Naveris to enter head and neck cancer testing. Shares have rebounded sharply, trading at $47.23 on Aug. 11 with a YTD gain of about 151% and strong one‑month and one‑year returns. » Mais em finance.yahoo.com

CareDx reports a revenue increase of more than 52% in Q2 and continues to focus on precision medicine for transplant-related monitoring tests. The acquisition of Naveris for up to $260 million marks the company’s strategic entry into oncology. An upcoming CMS decision on reimbursements could further boost demand for the tests. » Mais em finanzen.net